By proceeding, you agree to our Terms of Use and Privacy Policy.
Expanding the Clinical Utility of HER2 as a Multi-Tumor Target, Overcoming Resistance Mechanisms & Optimizing Pharmacology of Next Generation Anti-HER2 Drugs The momentum in anti-HER2 drug development is impossible to ignore: Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics, trial design and
The scope for HER2-targeted therapies is now immense. The experts in the event will expand the clinical utility of your pipeline by exploring HER2.
With the speakers, you can expand your utility, development and application of HER2 as a multi-tumor target to scale future pharma scope.
Network with pharma and clinical experts to partner for the future development and application of HER2-targeted therapies.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Natera is a global leader in providing DNA testing across multiple clinical areas including women's health, organ health, and oncology.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.